First treatment for thyroid eye disease gets FDA approval

The FDA Jan. 21 approved  Horizon Therapeutics’ drug, Tepezza, the first drug designed to treat thyroid eye disease.

Advertisement

Thyroid eye disease is a rare disease where muscles and fatty tissues behind the eyes become inflamed and cause the eyes to push forward and bulge outward. It can cause eye pain, double vision, light sensitivity or difficulty closing the eye. 

The disease affects more women than men and can be incapacitating, preventing people from driving or working. 

Tepezza is the first drug to be approved by the FDA to treat thyroid eye disease. 

Read the full article here.

More articles on pharmacy:
Walgreens, CVS demands led Ohio Medicaid to drop 272 pharmacies, state says
How Civica Rx became a force in the generic drug industry: A timeline
10 most expensive drugs for Medicare Part D

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.